Leflunomid Bluefish

Leflunomide, the active ingredient in Leflunomid Bluefish, is an immunomodulator presented as an oral tablet for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients, helping to reduce disease activity and joint damage.

GNH USA supplies Leflunomid Bluefish as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug used in autoimmune joint disorders.

Rheumatoid arthritis: reduces inflammation, slows radiographic progression, and improves functional status. Psoriatic arthritis: alleviates joint pain and skin lesions, improving overall disease control.

Leflunomide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Diarrhoea: loose stools, often mild to moderate. - Nausea: feeling of sickness, may be transient. - Alopecia: thinning or loss of hair. - Rash: skin redness or itching.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe infections: opportunistic or bacterial infections requiring medical attention. - Pulmonary toxicity: interstitial lung disease or pneumonitis.

Before initiating therapy, clinicians should assess patient risk factors and monitor key parameters. - Pregnancy: contraindicated (Category X); avoid in women of childbearing potential. - Liver function: obtain baseline tests and monitor periodically. - Hematology: perform regular complete blood counts to detect cytopenias. - Infection risk: avoid use in active severe infections. - Renal impairment: dose adjustment may be required in severe renal dysfunction. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Leflunomide can alter the activity of several co‑administered medicines.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Cholestyramine or other bile‑acid sequestrants: markedly reduces leflunomide exposure. - Live vaccines: heightened risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely): - Methotrexate: additive hepatotoxicity; monitor liver enzymes. - Azathioprine: potential for enhanced bone‑marrow suppression. - Cyclosporine: may increase leflunomide plasma levels. - NSAIDs: increased risk of gastrointestinal irritation.